The authors demonstrate small molecules that can block the binding of H-Ras.GTP to c-Raf1 both in vitro and in vivo, that inhibit multiple Ras-driven pathways in cells, and that are orally active against a K-Ras mutation positive colon carcinoma xenograft. Here, KRAS is linked to colon carcinoma.